Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTH NASDAQ:INDV NASDAQ:KNSA NASDAQ:URGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$86.88+1.6%$81.01$16.64▼$96.50$4.76B1.18927,407 shs72,751 shsINDVIndivior$39.08-1.3%$32.24$10.63▼$41.00$4.77B0.92.36 million shs161,824 shsKNSAKiniksa Pharmaceuticals International$57.82+1.6%$47.06$24.85▼$58.26$4.43B0.17703,274 shs62,426 shsURGNUrogen Pharma$28.75+8.1%$20.59$3.42▼$30.45$1.40B1.58808,533 shs842,620 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-5.47%-2.65%-0.85%+68.41%+327.99%INDVIndivior-2.49%+7.67%+29.96%+15.25%+244.50%KNSAKiniksa Pharmaceuticals International-2.23%+5.86%+16.33%+32.12%+112.66%URGNUrogen Pharma+1.30%+11.58%+47.48%+24.54%+162.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$86.88+1.6%$81.01$16.64▼$96.50$4.76B1.18927,407 shs72,751 shsINDVIndivior$39.08-1.3%$32.24$10.63▼$41.00$4.77B0.92.36 million shs161,824 shsKNSAKiniksa Pharmaceuticals International$57.82+1.6%$47.06$24.85▼$58.26$4.43B0.17703,274 shs62,426 shsURGNUrogen Pharma$28.75+8.1%$20.59$3.42▼$30.45$1.40B1.58808,533 shs842,620 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics-5.47%-2.65%-0.85%+68.41%+327.99%INDVIndivior-2.49%+7.67%+29.96%+15.25%+244.50%KNSAKiniksa Pharmaceuticals International-2.23%+5.86%+16.33%+32.12%+112.66%URGNUrogen Pharma+1.30%+11.58%+47.48%+24.54%+162.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 3.00Buy$117.8235.62% UpsideINDVIndivior 3.00Buy$39.330.66% UpsideKNSAKiniksa Pharmaceuticals International 2.67Moderate Buy$60.865.26% UpsideURGNUrogen Pharma 2.78Moderate Buy$35.2522.59% UpsideCurrent Analyst Ratings BreakdownLatest URGN, INDV, DNTH, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026URGNUrogen Pharma OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$34.00 ➝ $40.005/6/2026INDVIndivior Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C+) ➝ Hold (C)5/6/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/6/2026DNTHDianthus Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$103.00 ➝ $105.004/29/2026KNSAKiniksa Pharmaceuticals International Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $64.004/29/2026KNSAKiniksa Pharmaceuticals International CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $60.004/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$58.00 ➝ $59.004/29/2026KNSAKiniksa Pharmaceuticals International Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $57.004/28/2026KNSAKiniksa Pharmaceuticals International Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$58.00 ➝ $71.004/24/2026URGNUrogen Pharma Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$1.34M3,554.72N/AN/A$11.41 per share7.61INDVIndivior$1.24B3.85$2.62 per share14.93($1.18) per share-33.11KNSAKiniksa Pharmaceuticals International$677.56M6.53$0.79 per share73.36$7.91 per share7.31URGNUrogen Pharma$140.49M9.97N/AN/A($2.25) per share-12.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$162.34M-$4.13N/AN/AN/A-12,998.50%-38.79%-36.32%5/11/2026 (Estimated)INDVIndivior$210M$1.9520.0810.62N/A19.44%-219.26%29.40%N/AKNSAKiniksa Pharmaceuticals International$59.01M$0.9064.3334.01N/A9.69%13.26%9.86%N/AURGNUrogen Pharma-$153.49M-$2.75N/A37.34N/A-94.83%N/A-67.26%N/ALatest URGN, INDV, DNTH, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026DNTHDianthus Therapeutics-$1.1029-$0.85+$0.2529-$0.85$0.40 million$0.46 million5/6/2026Q1 2026URGNUrogen Pharma-$0.4824-$0.47+$0.0124-$0.47$44.83 million$50.96 million4/30/2026Q1 2026INDVIndivior$0.64$0.96+$0.32$3.45$272.84 million$317.00 million4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 million3/31/2026Q1 2026INDVIndiviorN/A$0.96N/A$3.45N/A$317.00 million3/9/2026Q4 2025DNTHDianthus Therapeutics-$0.97-$1.43-$0.46-$1.43$0.40 million$0.57 million3/2/2026Q4 2025URGNUrogen Pharma-$0.66-$0.54+$0.12-$0.54$39.92 million$37.84 million2/27/2026Q4 2025INDVIndivior$0.65$0.82+$0.17$3.95$305.62 million$358.00 million2/24/2026Q4 2025KNSAKiniksa Pharmaceuticals International$0.29$0.17-$0.12$0.17$200.86 million$202.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AURGNUrogen PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A13.3213.32INDVIndiviorN/A0.860.66KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33URGNUrogen PharmaN/A4.013.65Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%INDVIndivior60.33%KNSAKiniksa Pharmaceuticals International53.95%URGNUrogen Pharma91.29%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics3.02%INDVIndivior0.74%KNSAKiniksa Pharmaceuticals International53.48%URGNUrogen Pharma4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8054.67 million52.81 millionOptionableINDVIndivior1,051121.92 million121.02 millionNot OptionableKNSAKiniksa Pharmaceuticals International22076.54 million35.60 millionOptionableURGNUrogen Pharma20048.72 million46.43 millionOptionableURGN, INDV, DNTH, and KNSA HeadlinesRecent News About These CompaniesUrogen Pharma (NASDAQ:URGN) Sets New 1-Year High Following Analyst Upgrade9 minutes ago | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given New $40.00 Price Target at OppenheimerMay 8 at 5:31 AM | americanbankingnews.comUroGen Pharma Earnings Call Highlights ZUSDURI SurgeMay 7 at 9:51 PM | tipranks.comUrogen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Oppenheimer Analyst SaysMay 7 at 9:16 AM | marketbeat.comUroGen Pharma to Present at Upcoming Investor ConferencesMay 7 at 8:00 AM | globenewswire.comUrogen Pharma Q1 Earnings Call HighlightsMay 7 at 4:17 AM | marketbeat.comUroGen Pharma Ltd. (URGN) Q1 2026 Earnings Call TranscriptMay 6 at 6:10 PM | seekingalpha.comUrogen Pharma (NASDAQ:URGN) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 6 at 3:27 PM | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Up 14% on Better-Than-Expected EarningsMay 6 at 2:33 PM | marketbeat.comUrogen Pharma (URGN) Reports Q1 Loss, Beats Revenue EstimatesMay 6 at 10:30 AM | zacks.comUroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and HighlightsMay 6 at 8:00 AM | globenewswire.comUrogen Pharma (URGN) Projected to Post Earnings on WednesdayMay 2, 2026 | americanbankingnews.comUrogen Pharma (URGN) Projected to Post Quarterly Earnings on WednesdayMay 2, 2026 | marketbeat.comUroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026April 29, 2026 | globenewswire.comHC Wainwright Predicts Urogen Pharma Q1 EarningsApril 27, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Rating Increased to Strong-Buy at Jefferies Financial GroupApril 25, 2026 | marketbeat.comHC Wainwright Predicts Urogen Pharma Q3 EarningsApril 24, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Up 9% - Should You Buy?April 20, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Given Average Recommendation of "Moderate Buy" by AnalystsApril 20, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Trading Down 4.5% - What's Next?April 13, 2026 | marketbeat.comUrogen Pharma (NASDAQ:URGN) Shares Gap Up - Time to Buy?April 10, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeURGN, INDV, DNTH, and KNSA Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$86.88 +1.41 (+1.64%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Indivior NASDAQ:INDV$39.08 -0.53 (-1.33%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Kiniksa Pharmaceuticals International NASDAQ:KNSA$57.82 +0.89 (+1.55%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Urogen Pharma NASDAQ:URGN$28.75 +2.16 (+8.14%) As of 11:27 AM Eastern This is a fair market value price provided by Massive. Learn more.UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
